Statement of Changes in Beneficial Ownership (4)
February 03 2022 - 5:37PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Trevejo Jose M. |
2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc.
[
TARS
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
CHIEF MEDICAL OFFICER |
|
(Last)
(First)
(Middle)
15540 LAGUNA CANYON ROAD, SUITE 160 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/1/2022 |
|
(Street)
IRVINE, CA 92618
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Employee Stock Option (right to buy) | $20.64 | 2/1/2022 | | A | | 116424 | | (1) | 1/31/2032 | Common Stock | 116424.0 | $0 | 116424 | D | |
| Restricted Stock Units | (2) | 2/1/2022 | | A | | 30197 | | (3) | (3) | Common Stock | 30197.0 | $0 | 30197 | D | |
| Explanation of Responses: |
| (1) | 25% of the option shares shall vest on February 1, 2023, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. |
| (2) | Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. |
| (3) | 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Trevejo Jose M.
15540 LAGUNA CANYON ROAD
SUITE 160
IRVINE, CA 92618 |
|
| CHIEF MEDICAL OFFICER |
|
Signatures
|
| /s/ Leonard M. Greenstein | | 2/3/2022 |
| **Signature of Reporting Person | Date |
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Apr 2023 to Apr 2024
